Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)
优化癌症筛查人群研究协调中心 (PROSPR) (U24)
基本信息
- 批准号:10380156
- 负责人:
- 金额:$ 82.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-15 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdministrative CoordinationAdvisory CommitteesAuthorshipBioinformaticsBiometryBreast Cancer Surveillance ConsortiumCancer ModelCaringCervical Cancer ScreeningClinicColorectal CancerCommon Data ElementComplexDataData AnalysesDevelopmentEarly Detection Research NetworkEffectivenessEpidemiologyEvaluationHealth Care CostsHealth Disparities ResearchHealth ServicesHealthcare SystemsIndividualInfrastructureInstitutionLeadLeadershipMalignant NeoplasmsMalignant neoplasm of cervix uteriMalignant neoplasm of lungMeasuresModelingMonitorMorbidity - disease rateOrganOrganizational PolicyOutcomePaperPatientsPerformancePersonsPopulation ResearchPositioning AttributePreparationProceduresProcessProviderPublishingReaction TimeRecording of previous eventsResearchResearch PersonnelResearch Project GrantsRoleSafetyScheduleScreening for cancerSiteStatistical MethodsSystemTeleconferencesTestingTimeUnited Statescancer epidemiologycolorectal cancer screeningdata harmonizationdata repositorydata sharingexperiencehealth care deliveryhealth care service organizationhealth information technologyhealth planimplementation scienceimprovedindividual patientmeetingsmortalitymultidisciplinarynovelscreeningscreening participationscreening servicessharing platformsuccessworking group
项目摘要
Project Summary
Cancer screening is a complex, multi-step process where benefits are maximized when each step is completed
successfully, but where sub-optimal outcomes are frequent as a result of breakdowns that can happen at any
point in this process. Screening is also impacted by factors beyond simply individual patients—including factors
at the provider-, practice-, and health plan/institution-level—and these so-called systems level factors can
impact the appropriate delivery of high quality cancer screening services. PROSPR was established to address
a number of critical questions related to the delivery of cancer screening in the United States, and our
PROSPR I Statistical Coordinating Center was central to many of the successes of this initiative including: 1)
Developing a trans-organ conceptual model of cancer screening processes, 2) Creating common data
elements and screening performance metrics, 3) Evaluating individual and systems-level factors impacting
screening performance, 4) Authorship and statistical support on 21 trans-network published papers, 2 under
review, and 17 in preparation; and 5) Establishing PROSPR data repositories and creating an infrastructure for
publicly sharing PROSPR data. Our PCC team has considerable expertise both in the leadership of large
coordinating centers and in each of the scientific fields relevant to PROSPR including health services/health
care delivery, implementation science, cancer epidemiology, health disparities research, biostatistics,
bioinformatics/health information technology, and the screening of colorectal, cervical, and lung cancers. Thus,
we are uniquely positioned to successfully execute all components of this coordinating center. The specific
aims of our PCC are to: 1) Provide administrative coordination for the PROSPR network and guidance in the
development of PROSPR’s governance, organization, and policies/procedures; 2) Lead the development of
common conceptualization and measures for: A. Assessing the role of systems-level factors that impact the
screening process. B. Assessing screening quality; 3) Facilitate trans-PROSPR research comparing the
screening process across at least 2 organ sites; and 4) Develop and implement processes and procedures to
share PROSPR data with qualified investigators outside of the PROSPR network. RELEVANCE: Improving
both the screening process and screening quality for cervical, colorectal, and lung cancers will reduce
mortality, morbidity, and health care costs associated with these cancers in the United States.
项目概要
癌症筛查是一个复杂的多步骤过程,完成每个步骤后效益就会最大化
成功,但由于随时可能发生故障而导致次优结果的情况经常发生
筛查过程中的关键点还受到患者个体以外的因素的影响。
在提供者、实践和健康计划/机构层面,这些所谓的系统层面因素可以
PROSPR 的建立是为了解决适当提供高质量癌症筛查服务的影响。
与美国癌症筛查相关的一些关键问题,以及我们的
PROSPR I 统计协调中心对该举措的许多成功至关重要,其中包括:1)
开发癌症筛查过程的跨器官概念模型,2) 创建通用数据
要素和筛选绩效指标,3)评估个人和系统层面的影响因素
筛选表现,4) 21 篇跨网络发表论文的作者身份和统计支持,其中 2 篇为
审查,17 正在准备;以及 5) 建立 PROSPR 数据存储库并创建基础设施
我们的 PCC 团队在大型企业的领导力方面拥有丰富的专业知识。
协调中心以及与 PROSPR 相关的每个科学领域,包括卫生服务/健康
护理服务、科学、癌症流行病学、健康差异研究、生物统计学、
生物信息学/健康信息技术,以及结直肠癌、宫颈癌和肺癌的筛查。
我们拥有独特的优势,能够成功执行该协调中心的所有组成部分。
我们 PCC 的目标是: 1) 为 PROSPR 网络提供行政协调并提供指导
制定 PROSPR 的治理、组织和政策/程序 2) 领导制定
共同概念化和措施: A. 评估影响系统级因素的作用
B. 评估筛选质量;3) 促进反式 PROSPR 研究的比较。
至少 2 个器官部位的筛查流程;以及 4) 制定并实施流程和程序
与 PROSPR 网络之外的合格研究人员共享 PROSPR 数据。
宫颈癌、结直肠癌和肺癌的筛查过程和筛查质量都将减少
美国与这些癌症相关的死亡率、发病率和医疗保健费用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher I Li其他文献
Sex hormones and risk of lung and colorectal cancers in women: a Mendelian randomization study
女性性激素与肺癌和结直肠癌的风险:孟德尔随机研究
- DOI:
10.21203/rs.3.rs-4083598/v1 - 发表时间:
2024-04-10 - 期刊:
- 影响因子:0
- 作者:
Marion Denos;Yi;Ben Brumpton;Yafang Li;D. Albanes;Andrea Burnett;Peter T Campbell;S. Küry;Christopher I Li;Emily White;Jewel N Samadder;Mark E. Jenkins;Xiao - 通讯作者:
Xiao
Cancer cell-intrinsic and immunological phenotypes determine clinical outcomes in basal-like breast cancer
癌细胞内在和免疫表型决定基底样乳腺癌的临床结果
- DOI:
10.2147/dmso.s282403 - 发表时间:
2024-09-13 - 期刊:
- 影响因子:0
- 作者:
Christopher I Li;Yuping Zhang;M. Cieslik;Yi;Lanbo Xiao;E. Cobain;Tzu C. Tang;Xuhong Cao;Peggy L. Porter;Jamie Guenthoer;D. Robinson;M. Arul;Chinnaiyan - 通讯作者:
Chinnaiyan
Statin use and risks of breast cancer recurrence and mortality.
他汀类药物的使用以及乳腺癌复发和死亡的风险。
- DOI:
10.1002/cncr.35362 - 发表时间:
2024-05-06 - 期刊:
- 影响因子:6.2
- 作者:
Hanbing Guo;K. Malone;S. Heckbert;Christopher I Li - 通讯作者:
Christopher I Li
Impact of Freeze-thaw Cycles and Storage Time on Plasma Samples Used in Mass Spectrometry Based Biomarker Discovery Projects
冻融循环和储存时间对基于质谱的生物标志物发现项目中使用的血浆样品的影响
- DOI:
- 发表时间:
2005 - 期刊:
- 影响因子:2
- 作者:
Breeana L. Mitchell;Yutaka Yasui;Christopher I Li;Annette L. Fitzpatrick;P. Lampe - 通讯作者:
P. Lampe
Identification of potential mediators of the relationship between body mass index and colorectal cancer: a Mendelian randomization analysis
体重指数与结直肠癌之间关系的潜在调节因素的识别:孟德尔随机分析
- DOI:
10.1093/ije/dyae067 - 发表时间:
2024-04-11 - 期刊:
- 影响因子:7.7
- 作者:
Emmanouil Bouras;D. Gill;Verena Zuber;N. Murphy;Niki L Dimou;K. Aleksandrova;Sarah J. Lewis;R. M. Martin;J. Yarmolinsky;D. Albanes;H. Brenner;S. Castellví;A. T. Chan;I. Cheng;S. Gruber;B. van Guelpen;Christopher I Li;L. Le Marchand;P. Newcomb;Shuji Ogino;A. Pellatt;Stephanie L. Schmit;Alicja Wolk;Anna H Wu;Ulrike Peters;Marc J. Gunter;K. Tsilidis - 通讯作者:
K. Tsilidis
Christopher I Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher I Li', 18)}}的其他基金
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
项目 1:按种族/民族发现基于肿瘤组织的新型致死性结直肠癌预测因子
- 批准号:
10244963 - 财政年份:2020
- 资助金额:
$ 82.22万 - 项目类别:
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
项目 1:按种族/民族发现基于肿瘤组织的新型致死性结直肠癌预测因子
- 批准号:
10044049 - 财政年份:2020
- 资助金额:
$ 82.22万 - 项目类别:
Translational Research Program in Colorectal Cancer Disparities
结直肠癌差异的转化研究计划
- 批准号:
10044047 - 财政年份:2020
- 资助金额:
$ 82.22万 - 项目类别:
Translational Research Program in Colorectal Cancer Disparities
结直肠癌差异的转化研究计划
- 批准号:
10244961 - 财政年份:2020
- 资助金额:
$ 82.22万 - 项目类别:
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
项目 1:按种族/民族发现基于肿瘤组织的新型致死性结直肠癌预测因子
- 批准号:
10466937 - 财政年份:2020
- 资助金额:
$ 82.22万 - 项目类别:
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
项目 1:按种族/民族发现基于肿瘤组织的新型致死性结直肠癌预测因子
- 批准号:
10601406 - 财政年份:2020
- 资助金额:
$ 82.22万 - 项目类别:
Translational Research Program in Colorectal Cancer Disparities
结直肠癌差异的转化研究计划
- 批准号:
10466935 - 财政年份:2020
- 资助金额:
$ 82.22万 - 项目类别:
Translational Research Program in Colorectal Cancer Disparities
结直肠癌差异的转化研究计划
- 批准号:
10601404 - 财政年份:2020
- 资助金额:
$ 82.22万 - 项目类别:
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)
优化癌症筛查人群研究协调中心 (PROSPR) (U24)
- 批准号:
9898340 - 财政年份:2018
- 资助金额:
$ 82.22万 - 项目类别:
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)
优化癌症筛查人群研究协调中心 (PROSPR) (U24)
- 批准号:
10642674 - 财政年份:2018
- 资助金额:
$ 82.22万 - 项目类别:
相似海外基金
Admin Core - Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
管理核心 - 自噬调节剂作为新型广谱抗感染剂
- 批准号:
9893810 - 财政年份:2020
- 资助金额:
$ 82.22万 - 项目类别:
MAE-WEST SCORE Leadership Administrative Core
MAE-WEST SCORE 领导力行政核心
- 批准号:
10198756 - 财政年份:2020
- 资助金额:
$ 82.22万 - 项目类别: